Physician profile
Daniel C Massiah
NPI 1063485969
$5,057.50
in general payments reported to CMS, 2019-2025
16 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $639 · 2021: $882 · 2022: $545 · 2023: $648 · 2024: $865 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268 · Travel and Lodging: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.03 |
| Travel and Lodging | $366.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,621.14 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $881.81 | 2019-2024 | Breztri, Airsupra, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.50 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Inspire Medical Systems, INC. | $658.52 | 2024 | Inspire |
| Philips North America LLC | $286.67 | 2019-2023 | |
| Genentech USA, INC. | $150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.58 | 2019 | |
| Merck Sharp & Dohme LLC | $134.90 | 2020-2025 | Keytruda |
| Alexion Pharmaceuticals, INC. | $122.19 | 2021 | |
| Amgen INC. | $107.44 | 2024 | Repatha |
| Abbott Laboratories | $100.87 | 2019 | |
| Advanced Respiratory, INC | $47.97 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $18.34 | 2019 | |
| Mylan Specialty L.P. | $17.33 | 2023 | Yupelri |
| Genzyme Corporation | $16.64 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Massiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.